Search research articles
Contact Us
Filters
Showing results (891-900 of 903) with videos related to
Page
of 91
Sort By:
JAMA Network Open
|
July 25, 2024
Reducing Central Nervous System-Active Medications to Prevent Falls and Injuries Among Older Adults: A Cluster Randomized Clinical Trial
Elizabeth A Phelan, Brian D Williamson, Benjamin H Balderson, et al.
The Journal of Biological Chemistry
|
October 23, 1997
Involvement of caspase-1 and caspase-3 in the production and processing of mature human interleukin 18 in monocytic THP.1 cells
K Akita, T Ohtsuki, Y Nukada, et al.
Journal of the American College of Cardiology
|
November 3, 2001
Relationship between plasma level of cardiotrophin-1 and left ventricular mass index in patients with dilated cardiomyopathy
T Tsutamoto, A Wada, K Maeda, et al.
Cancer Causes & Control : CCC
|
November 1, 2019
Changes in use of opioid therapy after colon cancer diagnosis: a population-based study
Lu Chen, Jessica Chubak, Onchee Yu, et al.
Cancer Causes & Control : CCC
|
September 24, 2018
Risk of colon cancer recurrence in relation to diabetes
Jessica Chubak, Onchee Yu, Rebecca A Ziebell, et al.
ESMO Open
|
May 7, 2025
Genome-wide DNA methylation status as a biomarker for clinical outcomes of first-line treatment in patients with RAS wild-type metastatic colorectal cancer: JACCRO CC-13AR
K Ouchi, Y Sunakawa, A Tsuji, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 2017
A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group
H Bleiberg, G Decoster, A de Gramont, et al.
ESMO Open
|
September 13, 2023
Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16
H Yasui, Y Okita, M Nakamura, et al.
ESMO Open
|
June 10, 2022
Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11)
Y Sunakawa, H Satake, J Usher, et al.
Cancers
|
September 14, 2024
A Patient-Centered Conceptual Model of AYA Cancer Survivorship Care Informed by a Qualitative Interview Study
Marlaine S Figueroa Gray, Lily Shapiro, Caitlin N Dorsey, et al.
Page
of 91
Search research articles
Search
Showing results (891-900 of 903) with videos related to
Sort By:
Page
of 91
JAMA Network Open
|
July 25, 2024
Reducing Central Nervous System-Active Medications to Prevent Falls and Injuries Among Older Adults: A Cluster Randomized Clinical Trial
Elizabeth A Phelan, Brian D Williamson, Benjamin H Balderson, et al.
The Journal of Biological Chemistry
|
October 23, 1997
Involvement of caspase-1 and caspase-3 in the production and processing of mature human interleukin 18 in monocytic THP.1 cells
K Akita, T Ohtsuki, Y Nukada, et al.
Journal of the American College of Cardiology
|
November 3, 2001
Relationship between plasma level of cardiotrophin-1 and left ventricular mass index in patients with dilated cardiomyopathy
T Tsutamoto, A Wada, K Maeda, et al.
Cancer Causes & Control : CCC
|
November 1, 2019
Changes in use of opioid therapy after colon cancer diagnosis: a population-based study
Lu Chen, Jessica Chubak, Onchee Yu, et al.
Cancer Causes & Control : CCC
|
September 24, 2018
Risk of colon cancer recurrence in relation to diabetes
Jessica Chubak, Onchee Yu, Rebecca A Ziebell, et al.
ESMO Open
|
May 7, 2025
Genome-wide DNA methylation status as a biomarker for clinical outcomes of first-line treatment in patients with RAS wild-type metastatic colorectal cancer: JACCRO CC-13AR
K Ouchi, Y Sunakawa, A Tsuji, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 2017
A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group
H Bleiberg, G Decoster, A de Gramont, et al.
ESMO Open
|
September 13, 2023
Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16
H Yasui, Y Okita, M Nakamura, et al.
ESMO Open
|
June 10, 2022
Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11)
Y Sunakawa, H Satake, J Usher, et al.
Cancers
|
September 14, 2024
A Patient-Centered Conceptual Model of AYA Cancer Survivorship Care Informed by a Qualitative Interview Study
Marlaine S Figueroa Gray, Lily Shapiro, Caitlin N Dorsey, et al.
Page
of 91